DNTH — Dianthus Therapeutics, Inc. stock price, charts and financials

QT59Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
110.40
+4.38+4.13%
OverviewShort InterestFilings
DNTHQT59Dianthus Therapeutics, Inc.·NASDAQ
110.40+4.13%

Latest SEC Filings

Form category
Filing Date ▾FormDescriptionFilingDocument
Jul 28, 2026SC 13G/ABeneficial ownership statement (passive, amended)
Jul 13, 20264Statement of changes in beneficial ownership
Jun 18, 20264Statement of changes in beneficial ownership
Jun 12, 20268-KCurrent report
Jun 02, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20268-KCurrent report
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 15, 2026SC 13GBeneficial ownership statement (passive)
May 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 14, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 11, 20264Statement of changes in beneficial ownership
May 05, 20268-KCurrent report
May 05, 202610-QQuarterly report
Apr 27, 2026SC 13GBeneficial ownership statement (passive)
Apr 10, 20264Statement of changes in beneficial ownership
Apr 09, 2026DEFA14AAdditional proxy soliciting materials
Apr 09, 2026DEF 14ADefinitive proxy statement
#1 / 25 of 171
Page
▼
/ 7